Sanara MedTech (SMTI) Competitors $23.17 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$23.40 +0.23 (+0.99%) As of 05/22/2026 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SMTI vs. SSII, AVR, SGP, SIBN, and CBLLShould you buy Sanara MedTech stock or one of its competitors? MarketBeat compares Sanara MedTech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sanara MedTech include SS Innovations International (SSII), Anteris Technologies Global (AVR), Spyglass Pharma (SGP), SiBone (SIBN), and CeriBell (CBLL). These companies are all part of the "medical equipment" industry. SMTI vs. SSIISMTI vs. AVRSMTI vs. SGPSMTI vs. SIBNSMTI vs. CBLLHow does Sanara MedTech compare to SS Innovations International?SS Innovations International (NASDAQ:SSII) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical equipment companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation. Which has preferable valuation and earnings, SSII or SMTI? SS Innovations International has higher earnings, but lower revenue than Sanara MedTech. SS Innovations International is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSS Innovations International$42.49M18.32-$12.13M-$0.05N/ASanara MedTech$103.12M2.06-$37.56M-$3.77N/A Is SSII or SMTI more profitable? SS Innovations International has a net margin of -20.69% compared to Sanara MedTech's net margin of -31.23%. Sanara MedTech's return on equity of -3.19% beat SS Innovations International's return on equity.Company Net Margins Return on Equity Return on Assets SS Innovations International-20.69% -23.00% -13.18% Sanara MedTech -31.23%-3.19%-0.56% Do insiders and institutionals believe in SSII or SMTI? 8.1% of Sanara MedTech shares are held by institutional investors. 42.0% of Sanara MedTech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media prefer SSII or SMTI? In the previous week, Sanara MedTech had 3 more articles in the media than SS Innovations International. MarketBeat recorded 3 mentions for Sanara MedTech and 0 mentions for SS Innovations International. SS Innovations International's average media sentiment score of 0.00 equaled Sanara MedTech'saverage media sentiment score. Company Overall Sentiment SS Innovations International Neutral Sanara MedTech Neutral Do analysts rate SSII or SMTI? Sanara MedTech has a consensus target price of $34.00, indicating a potential upside of 46.74%. Given Sanara MedTech's stronger consensus rating and higher possible upside, analysts clearly believe Sanara MedTech is more favorable than SS Innovations International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SS Innovations International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Sanara MedTech 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummarySanara MedTech beats SS Innovations International on 10 of the 14 factors compared between the two stocks.How does Sanara MedTech compare to Anteris Technologies Global?Sanara MedTech (NASDAQ:SMTI) and Anteris Technologies Global (NASDAQ:AVR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation. Which has more risk & volatility, SMTI or AVR? Sanara MedTech has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market. Comparatively, Anteris Technologies Global has a beta of 1.32, indicating that its share price is 32% more volatile than the broader market. Is SMTI or AVR more profitable? Sanara MedTech has a net margin of -31.23% compared to Anteris Technologies Global's net margin of -5,148.78%. Sanara MedTech's return on equity of -3.19% beat Anteris Technologies Global's return on equity.Company Net Margins Return on Equity Return on Assets Sanara MedTech-31.23% -3.19% -0.56% Anteris Technologies Global -5,148.78%-124.76%-101.21% Do analysts prefer SMTI or AVR? Sanara MedTech presently has a consensus price target of $34.00, indicating a potential upside of 46.74%. Anteris Technologies Global has a consensus price target of $16.00, indicating a potential upside of 66.32%. Given Anteris Technologies Global's stronger consensus rating and higher possible upside, analysts plainly believe Anteris Technologies Global is more favorable than Sanara MedTech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sanara MedTech 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00Anteris Technologies Global 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Does the media prefer SMTI or AVR? In the previous week, Anteris Technologies Global had 1 more articles in the media than Sanara MedTech. MarketBeat recorded 4 mentions for Anteris Technologies Global and 3 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 0.00 beat Anteris Technologies Global's score of -0.20 indicating that Sanara MedTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanara MedTech 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Anteris Technologies Global 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger valuation & earnings, SMTI or AVR? Sanara MedTech has higher revenue and earnings than Anteris Technologies Global. Sanara MedTech is trading at a lower price-to-earnings ratio than Anteris Technologies Global, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSanara MedTech$103.12M2.06-$37.56M-$3.77N/AAnteris Technologies Global$1.85M505.90-$94.14M-$2.23N/A Do insiders and institutionals have more ownership in SMTI or AVR? 8.1% of Sanara MedTech shares are owned by institutional investors. 42.0% of Sanara MedTech shares are owned by insiders. Comparatively, 4.5% of Anteris Technologies Global shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummarySanara MedTech and Anteris Technologies Global tied by winning 8 of the 16 factors compared between the two stocks.How does Sanara MedTech compare to Spyglass Pharma?Spyglass Pharma (NASDAQ:SGP) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical equipment companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation. Is SGP or SMTI more profitable? Spyglass Pharma has a net margin of 0.00% compared to Sanara MedTech's net margin of -31.23%. Spyglass Pharma's return on equity of 0.00% beat Sanara MedTech's return on equity.Company Net Margins Return on Equity Return on Assets Spyglass PharmaN/A N/A N/A Sanara MedTech -31.23%-3.19%-0.56% Do insiders & institutionals believe in SGP or SMTI? 8.1% of Sanara MedTech shares are held by institutional investors. 42.0% of Sanara MedTech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media favor SGP or SMTI? In the previous week, Sanara MedTech had 1 more articles in the media than Spyglass Pharma. MarketBeat recorded 3 mentions for Sanara MedTech and 2 mentions for Spyglass Pharma. Spyglass Pharma's average media sentiment score of 0.00 equaled Sanara MedTech'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyglass Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sanara MedTech 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable earnings and valuation, SGP or SMTI? Spyglass Pharma has higher earnings, but lower revenue than Sanara MedTech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpyglass PharmaN/AN/AN/AN/AN/ASanara MedTech$103.12M2.06-$37.56M-$3.77N/A Do analysts rate SGP or SMTI? Spyglass Pharma presently has a consensus price target of $45.00, indicating a potential upside of 115.93%. Sanara MedTech has a consensus price target of $34.00, indicating a potential upside of 46.74%. Given Spyglass Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Spyglass Pharma is more favorable than Sanara MedTech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spyglass Pharma 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Sanara MedTech 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummarySpyglass Pharma beats Sanara MedTech on 6 of the 10 factors compared between the two stocks.How does Sanara MedTech compare to SiBone?SiBone (NASDAQ:SIBN) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk. Is SIBN or SMTI more profitable? SiBone has a net margin of -8.10% compared to Sanara MedTech's net margin of -31.23%. Sanara MedTech's return on equity of -3.19% beat SiBone's return on equity.Company Net Margins Return on Equity Return on Assets SiBone-8.10% -9.56% -7.06% Sanara MedTech -31.23%-3.19%-0.56% Does the media prefer SIBN or SMTI? In the previous week, SiBone and SiBone both had 3 articles in the media. Sanara MedTech's average media sentiment score of 0.00 beat SiBone's score of -0.70 indicating that Sanara MedTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SiBone 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Sanara MedTech 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders have more ownership in SIBN or SMTI? 98.1% of SiBone shares are owned by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are owned by institutional investors. 4.0% of SiBone shares are owned by company insiders. Comparatively, 42.0% of Sanara MedTech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts rate SIBN or SMTI? SiBone presently has a consensus target price of $23.00, suggesting a potential upside of 56.68%. Sanara MedTech has a consensus target price of $34.00, suggesting a potential upside of 46.74%. Given SiBone's stronger consensus rating and higher possible upside, analysts plainly believe SiBone is more favorable than Sanara MedTech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SiBone 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71Sanara MedTech 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk & volatility, SIBN or SMTI? SiBone has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market. Which has preferable valuation & earnings, SIBN or SMTI? SiBone has higher revenue and earnings than Sanara MedTech. SiBone is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSiBone$200.93M3.24-$18.90M-$0.39N/ASanara MedTech$103.12M2.06-$37.56M-$3.77N/A SummarySiBone beats Sanara MedTech on 9 of the 15 factors compared between the two stocks.How does Sanara MedTech compare to CeriBell?CeriBell (NASDAQ:CBLL) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations. Which has more risk and volatility, CBLL or SMTI? CeriBell has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market. Comparatively, Sanara MedTech has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market. Do institutionals and insiders hold more shares of CBLL or SMTI? 8.1% of Sanara MedTech shares are owned by institutional investors. 20.1% of CeriBell shares are owned by company insiders. Comparatively, 42.0% of Sanara MedTech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is CBLL or SMTI more profitable? Sanara MedTech has a net margin of -31.23% compared to CeriBell's net margin of -63.51%. Sanara MedTech's return on equity of -3.19% beat CeriBell's return on equity.Company Net Margins Return on Equity Return on Assets CeriBell-63.51% -38.19% -30.92% Sanara MedTech -31.23%-3.19%-0.56% Do analysts rate CBLL or SMTI? CeriBell presently has a consensus target price of $22.20, indicating a potential upside of 18.27%. Sanara MedTech has a consensus target price of $34.00, indicating a potential upside of 46.74%. Given Sanara MedTech's higher possible upside, analysts clearly believe Sanara MedTech is more favorable than CeriBell.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CeriBell 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83Sanara MedTech 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media favor CBLL or SMTI? In the previous week, CeriBell and CeriBell both had 3 articles in the media. CeriBell's average media sentiment score of 0.20 beat Sanara MedTech's score of 0.00 indicating that CeriBell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CeriBell 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sanara MedTech 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better earnings & valuation, CBLL or SMTI? Sanara MedTech has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Sanara MedTech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCeriBell$89.06M8.00-$53.41M-$1.63N/ASanara MedTech$103.12M2.06-$37.56M-$3.77N/A SummarySanara MedTech beats CeriBell on 10 of the 16 factors compared between the two stocks. Get Sanara MedTech News Delivered to You Automatically Sign up to receive the latest news and ratings for SMTI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SMTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SMTI vs. The Competition ExportMetricSanara MedTechMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$212.24M$8.36B$6.43B$12.32BDividend YieldN/A2.50%2.76%5.28%P/E Ratio-6.1516.2421.0125.66Price / Sales2.066.38615.84111.99Price / Cash38.9717.1143.4956.67Price / Book30.094.0610.377.14Net Income-$37.56M$224.05M$3.57B$335.98M7 Day Performance5.85%4.68%6.01%3.56%1 Month Performance20.55%-0.08%3.52%2.54%1 Year Performance-23.76%0.98%34.13%35.05% Sanara MedTech Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SMTISanara MedTech2.1537 of 5 stars$23.17flat$34.00+46.7%-23.8%$212.24M$103.12MN/A60SSIISS Innovations International1.1354 of 5 stars$3.99-0.4%N/A-55.9%$797.52M$42.49MN/A4AVRAnteris Technologies Global3.1057 of 5 stars$7.85+1.9%$16.00+104.0%+164.3%$763.54M$1.91MN/A138Gap DownSGPSpyglass PharmaN/A$21.75-2.2%$45.00+106.9%N/A$727.00MN/AN/A65Gap UpSIBNSiBone2.3446 of 5 stars$14.91+0.4%$23.00+54.3%-20.1%$660.99M$200.93MN/A350 Related Companies and Tools Related Companies SS Innovations International Competitors Anteris Technologies Global Competitors Spyglass Pharma Competitors SiBone Competitors CeriBell Competitors Brainsway Competitors NeuroPace Competitors MiMedx Group Competitors Tactile Systems Technology Competitors OrthoPediatrics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SMTI) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sanara MedTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sanara MedTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
